Sign In

Login

Password

Forgot Password ? Sign Up

Icrucumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Icrucumab" in English language version.

refsWebsite
Global rank English rank
1ama-assn.org
3,257th place
3,398th place
1doi.org
2nd place
2nd place
1nih.gov
4th place
4th place
1semanticscholar.org
11th place
8th place
1clinicaltrials.gov
5,225th place
4,062nd place

ama-assn.org

  • "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.

clinicaltrials.gov

  • Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov

doi.org

  • LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897. S2CID 34756277.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897. S2CID 34756277.

semanticscholar.org

api.semanticscholar.org

  • LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897. S2CID 34756277.